Literature DB >> 22193408

BRCA1 and BRCA2: different roles in a common pathway of genome protection.

Rohini Roy1, Jarin Chun, Simon N Powell.   

Abstract

The proteins encoded by the two major breast cancer susceptibility genes, BRCA1 and BRCA2, work in a common pathway of genome protection. However, the two proteins work at different stages in the DNA damage response (DDR) and in DNA repair. BRCA1 is a pleiotropic DDR protein that functions in both checkpoint activation and DNA repair, whereas BRCA2 is a mediator of the core mechanism of homologous recombination. The links between the two proteins are not well understood, but they must exist to explain the marked similarity of human cancer susceptibility that arises with germline mutations in these genes. As discussed here, the proteins work in concert to protect the genome from double-strand DNA damage during DNA replication.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22193408      PMCID: PMC4972490          DOI: 10.1038/nrc3181

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  112 in total

Review 1.  Roles of BRCA1 and its interacting proteins.

Authors:  C X Deng; S G Brodie
Journal:  Bioessays       Date:  2000-08       Impact factor: 4.345

2.  BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene.

Authors:  J N Snouwaert; L C Gowen; A M Latour; A R Mohn; A Xiao; L DiBiase; B H Koller
Journal:  Oncogene       Date:  1999-12-20       Impact factor: 9.867

3.  Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies.

Authors:  Henning Willers; Alphonse G Taghian; Chen-Mei Luo; Alejandro Treszezamsky; Dennis C Sgroi; Simon N Powell
Journal:  Mol Cancer Res       Date:  2009-08-11       Impact factor: 5.852

4.  Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer.

Authors:  M Krainer; S Silva-Arrieta; M G FitzGerald; A Shimada; C Ishioka; R Kanamaru; D J MacDonald; H Unsal; D M Finkelstein; A Bowcock; K J Isselbacher; D A Haber
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

5.  Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.

Authors:  D Cortez; Y Wang; J Qin; S J Elledge
Journal:  Science       Date:  1999-11-05       Impact factor: 47.728

6.  The BRCA2 homologue Brh2 nucleates RAD51 filament formation at a dsDNA-ssDNA junction.

Authors:  Haijuan Yang; Qiubai Li; Jie Fan; William K Holloman; Nikola P Pavletich
Journal:  Nature       Date:  2005-02-10       Impact factor: 49.962

7.  Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.

Authors:  E Comen; M Davids; T Kirchhoff; C Hudis; K Offit; M Robson
Journal:  Breast Cancer Res Treat       Date:  2011-03-11       Impact factor: 4.872

8.  Uterus hyperplasia and increased carcinogen-induced tumorigenesis in mice carrying a targeted mutation of the Chk2 phosphorylation site in Brca1.

Authors:  Sang Soo Kim; Liu Cao; Cuiling Li; Xiaoling Xu; L Julie Huber; Lewis A Chodosh; Chu-Xia Deng
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

9.  BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.

Authors:  Haijuan Yang; Philip D Jeffrey; Julie Miller; Elspeth Kinnucan; Yutong Sun; Nicolas H Thoma; Ning Zheng; Phang-Lang Chen; Wen-Hwa Lee; Nikola P Pavletich
Journal:  Science       Date:  2002-09-13       Impact factor: 47.728

10.  CCDC98 targets BRCA1 to DNA damage sites.

Authors:  Zixing Liu; Jiaxue Wu; Xiaochun Yu
Journal:  Nat Struct Mol Biol       Date:  2007-07-22       Impact factor: 15.369

View more
  512 in total

1.  Initiation, evolution, phenotype and outcome of BRCA1 and BRCA2 mutation-associated breast cancer.

Authors:  Ke-Da Yu; Zhi-Ming Shao
Journal:  Nat Rev Cancer       Date:  2012-05-24       Impact factor: 60.716

2.  BRCA1 and BRCA2: a common pathway of genome protection but different breast cancer subtypes.

Authors:  Simon A Joosse
Journal:  Nat Rev Cancer       Date:  2012-05-24       Impact factor: 60.716

Review 3.  Functional assays for analysis of variants of uncertain significance in BRCA2.

Authors:  Lucia Guidugli; Aura Carreira; Sandrine M Caputo; Asa Ehlen; Alvaro Galli; Alvaro N A Monteiro; Susan L Neuhausen; Thomas V O Hansen; Fergus J Couch; Maaike P G Vreeswijk
Journal:  Hum Mutat       Date:  2013-12-03       Impact factor: 4.878

Review 4.  Non-homologous end joining: emerging themes and unanswered questions.

Authors:  Sarvan Kumar Radhakrishnan; Nicholas Jette; Susan P Lees-Miller
Journal:  DNA Repair (Amst)       Date:  2014-02-26

Review 5.  BRCA1 Mutation: A Predictive Marker for Radiation Therapy?

Authors:  Charlene Kan; Junran Zhang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-10-01       Impact factor: 7.038

6.  Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.

Authors:  Angel Chao; Chyong-Huey Lai; Tzu-Hao Wang; Shih-Ming Jung; Yun-Shien Lee; Wei-Yang Chang; Lan-Yang Yang; Fei-Chun Ku; Huei-Jean Huang; An-Shine Chao; Chin-Jung Wang; Ting-Chang Chang; Ren-Chin Wu
Journal:  J Mol Med (Berl)       Date:  2018-05-03       Impact factor: 4.599

7.  Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A case report.

Authors:  Amir Sonnenblick; Aviad Zick; Myriam Maoz; Sherri Cohen; Luna Kadouri; Tamar Peretz; Ayala Hubert
Journal:  Mol Clin Oncol       Date:  2018-03-09

8.  Synthetic lethality between CCNE1 amplification and loss of BRCA1.

Authors:  Dariush Etemadmoghadam; Barbara A Weir; George Au-Yeung; Kathryn Alsop; Gillian Mitchell; Joshy George; Sally Davis; Alan D D'Andrea; Kaylene Simpson; William C Hahn; David D L Bowtell
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

9.  The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.

Authors:  Ciric To; Eun-Hee Kim; Darlene B Royce; Charlotte R Williams; Ryan M Collins; Renee Risingsong; Michael B Sporn; Karen T Liby
Journal:  Cancer Prev Res (Phila)       Date:  2014-05-09

10.  Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.

Authors:  Poorval M Joshi; Shari L Sutor; Catherine J Huntoon; Larry M Karnitz
Journal:  J Biol Chem       Date:  2014-02-19       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.